Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United States
Open Access
- 19 November 2025
- journal article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 1989-1998
Abstract
Patients with refractory multiple myeloma (MM) often progress through lines of therapy (LOTs) comprising multiple drug classes, which may impose severe economic burden. In this retrospective US claims database study, we examined healthcare resource utilization (HCRU) and costs of patients with MM who received 1 to 3 prior LOTs. Adults with MM from the IBM Truven MarketScan Claims Database (January 1, 2011-April 22, 2023) were required to be continuously enrolled in a medical benefit/pharmacy plan for ≥12 months before initial MM diagnosis date and to have received 1 to 3 LOTs (including receiving ≥1 proteasome inhibitor and immunomodulatory drug and receiving and discontinuing lenalidomide) after diagnosis date. Index dates (start of subsequent treatment after fulfilling inclusion criteria) occurred after January 1, 2018, to capture contemporary cost estimates. Primary outcomes included all-cause and MM-related healthcare costs and HCRU after index date. The primary analysis included 338 patients with MM without post-index stem cell transplant (SCT), with a mean age of 61.1 years (55.3% male). During an average follow-up of 11.5 months, total all-cause healthcare costs averaged US $41,614 per patient per month. MM-related healthcare costs ($39,699) contributed 95% to total all-cause costs. Most MM-related monthly costs were attributed to drug/infusion costs (71%; $28,144). Sensitivity analyses that included patients with post-index SCT (N = 520) yielded similar results. Patients with MM with 1 to 3 prior LOTs experienced high economic burden largely attributable to MM-related treatment, highlighting the need for more cost-effective therapies.Keywords
Funding Information
- Janssen Scientific Affairs
- Legend Biotech
This publication has 30 references indexed in Scilit:
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaNew England Journal of Medicine, 2023
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaNew England Journal of Medicine, 2023
- Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United StatesOncology and Therapy, 2022
- Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the USOncology and Therapy, 2021
- Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the USJAMA Network Open, 2021
- Multiple myeloma current treatment algorithmsBlood Cancer Journal, 2020
- Burden of disease progression in patients with multiple myeloma in the USLeukemia & Lymphoma, 2019
- Economic burden of multiple myeloma among patients in successive lines of therapy in the United StatesLeukemia & Lymphoma, 2017
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG studyLeukemia, 2017
- Trends in overall survival and costs of multiple myeloma, 2000–2014Leukemia, 2016